drugset
drugset / Trial / NCT04705597

Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure

NCT04705597 ↗

Phase 2 Terminated 194 enrolled BioAge Labs, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of BGE-175 in participants ≥ 50 years of age hospitalized with documented COVID-19.

Timeline

Start
2021-03-18
Primary completion
2022-04-20
Completion
2022-05-19

Drugs

EvaluationDrugModalityDoseRoute
Subject ASAPIPRANT Small molecule — Oral

Indications

COVID-19